JP2012525829A - 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 - Google Patents

補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 Download PDF

Info

Publication number
JP2012525829A
JP2012525829A JP2012509035A JP2012509035A JP2012525829A JP 2012525829 A JP2012525829 A JP 2012525829A JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012509035 A JP2012509035 A JP 2012509035A JP 2012525829 A JP2012525829 A JP 2012525829A
Authority
JP
Japan
Prior art keywords
antibody
binding
antigen
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012509035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525829A5 (enExample
Inventor
ビジャン・エテマド−ギルバートソン
ブレイドン・チャールズ・ギルド
キム・ヨンイン
インゴ・クラゲ
アレクサンドラ・クラウス
マイケル・ログスカ
イゴル・スプラフスキー
チャオ・ケハオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2012525829A publication Critical patent/JP2012525829A/ja
Publication of JP2012525829A5 publication Critical patent/JP2012525829A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012509035A 2009-05-06 2010-05-05 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法 Pending JP2012525829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06
US61/175,860 2009-05-06
PCT/EP2010/056129 WO2010136311A2 (en) 2009-05-06 2010-05-05 Compositions and methods for antibodies targeting complement protein c3b

Publications (2)

Publication Number Publication Date
JP2012525829A true JP2012525829A (ja) 2012-10-25
JP2012525829A5 JP2012525829A5 (enExample) 2013-06-20

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012509035A Pending JP2012525829A (ja) 2009-05-06 2010-05-05 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法

Country Status (22)

Country Link
US (1) US20100291106A1 (enExample)
EP (1) EP2427491A2 (enExample)
JP (1) JP2012525829A (enExample)
KR (1) KR20120088551A (enExample)
CN (1) CN102459334A (enExample)
AR (1) AR076655A1 (enExample)
AU (1) AU2010252156A1 (enExample)
CA (1) CA2760757A1 (enExample)
CL (1) CL2011002756A1 (enExample)
CO (1) CO6440515A2 (enExample)
EA (1) EA201101593A1 (enExample)
EC (1) ECSP11011445A (enExample)
IL (1) IL216061A0 (enExample)
MA (1) MA33402B1 (enExample)
MX (1) MX2011011754A (enExample)
PE (1) PE20120899A1 (enExample)
SG (1) SG175432A1 (enExample)
TN (1) TN2011000528A1 (enExample)
TW (1) TW201043638A (enExample)
UY (1) UY32612A (enExample)
WO (1) WO2010136311A2 (enExample)
ZA (1) ZA201107551B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
JP2021520195A (ja) * 2018-04-03 2021-08-19 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
AU2007261315B2 (en) 2006-06-21 2012-10-25 Musc Foundation For Research Development Targeting complement factor H for treatment of diseases
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
NZ603560A (en) 2010-05-14 2014-09-26 Univ Colorado Regents Improved complement receptor 2 (cr2) targeting groups
CN103249432A (zh) 2010-06-22 2013-08-14 科罗拉多大学董事会,法人团体 补体成分3的C3d片段的抗体
WO2012075023A2 (en) * 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
JP6262715B2 (ja) * 2012-04-03 2018-01-17 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP2912065A4 (en) 2012-10-25 2016-10-19 True North Therapeutics Inc ANTI COMPLEMENT C1S ANTIBODIES AND USES THEREOF
JP6543572B2 (ja) 2012-11-02 2019-07-10 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
USRE49099E1 (en) * 2012-11-29 2022-06-07 Bayer Healthcare Llc Humanized monoclonal antibodies against activated protein c and uses thereof
EP2978451B1 (en) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EA034870B1 (ru) 2013-08-07 2020-03-31 Алексион Фармасьютикалз, Инк. Белковые биомаркеры атипичного гемолитического уремического синдрома
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
HRP20251304T1 (hr) 2016-10-12 2025-12-05 Bioverativ Usa Inc. Anti-c1s protutijela i postupci njihove upotrebe
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
WO2019238674A1 (en) * 2018-06-11 2019-12-19 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3214281A1 (en) * 2021-03-19 2022-09-22 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof
JP2024546183A (ja) 2021-12-22 2024-12-17 ツェーデーエァ－ライフ アクチェンゲゼルシャフト 抗ｃ３抗体及びその抗原結合性断片並びに眼科疾患又は眼疾患を処置するためのそれらの使用
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
KR20250069553A (ko) * 2022-09-20 2025-05-19 비스테라, 인크. C3b-항체를 이용하는 보체 매개 질환 및 장애의 치료

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503089A (ja) * 1986-04-11 1988-11-10 ニルソン，ウルフ，エル ヒトｃ３中のある抗原決定基に対する抗体調製物及びその使用並びにその生産
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2008118711A2 (en) * 2007-03-23 2008-10-02 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof
WO2008154251A2 (en) * 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009056631A2 (en) * 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating complement component

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1287364B1 (en) * 2000-04-29 2008-10-22 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
EP1863847A2 (en) * 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
RU2425841C2 (ru) * 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63503089A (ja) * 1986-04-11 1988-11-10 ニルソン，ウルフ，エル ヒトｃ３中のある抗原決定基に対する抗体調製物及びその使用並びにその生産
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
WO2008118711A2 (en) * 2007-03-23 2008-10-02 Novelmed Therapeutics, Inc. Method of inhibiting complement activation with human anti-factor c3 antibodies and use thereof
WO2008154251A2 (en) * 2007-06-07 2008-12-18 Genentech, Inc. C3b antibodies and methods for the prevention and treatment of complement- associated disorders
WO2009056631A2 (en) * 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating complement component

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014039079; ＴＯＳＩＣ，　Ｌ．，　ｅｔ　ａｌ．: Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ １２０, 1989, ｐｐ．２４１-２４９ *
JPN6014039080; ＷＡＲＬ，　Ｋ．Ｌ．，　ｅｔ　ａｌ．: Ａｄｖａｎｃｅｄ　Ｄｒｕｇ　Ｄｅｌｉｖｅｒｙ　Ｒｅｖｉｅｗｓ ５８, 2006, ｐｐ．６５７-６７０ *
JPN6014039081; ＫＡＴＳＣＨＫＥ，　Ｋ．Ｊ．，　Ｊｒ．，　ｅｔ　ａｌ．: Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． ２８４, 2009, ｐｐ．１０４７３-１０４７９ *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502023A (ja) * 2013-12-24 2017-01-19 ノーベルメッド セラピューティクス インコーポレイテッド． 眼疾患を治療する組成物および方法
US10183989B2 (en) 2013-12-24 2019-01-22 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
US10696740B2 (en) 2013-12-24 2020-06-30 Novelmed Therapeutics, Inc. Methods of treating ocular diseases
JP2021520195A (ja) * 2018-04-03 2021-08-19 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
US11767359B2 (en) 2018-04-03 2023-09-26 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
JP7477457B2 (ja) 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法

Also Published As

Publication number Publication date
ZA201107551B (en) 2012-07-25
CA2760757A1 (en) 2010-12-02
SG175432A1 (en) 2011-12-29
WO2010136311A2 (en) 2010-12-02
EP2427491A2 (en) 2012-03-14
CL2011002756A1 (es) 2012-03-23
IL216061A0 (en) 2012-01-31
UY32612A (es) 2010-12-31
AR076655A1 (es) 2011-06-29
WO2010136311A3 (en) 2011-05-26
MX2011011754A (es) 2011-11-29
PE20120899A1 (es) 2012-08-03
MA33402B1 (fr) 2012-07-03
CN102459334A (zh) 2012-05-16
KR20120088551A (ko) 2012-08-08
TW201043638A (en) 2010-12-16
ECSP11011445A (es) 2012-01-31
EA201101593A1 (ru) 2012-06-29
US20100291106A1 (en) 2010-11-18
CO6440515A2 (es) 2012-05-15
AU2010252156A1 (en) 2011-11-10
TN2011000528A1 (en) 2013-05-24

Similar Documents

Publication Publication Date Title
JP6224657B2 (ja) 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法
JP2012525829A (ja) 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法
CN104114576B (zh) 用于抗体靶定p因子的组合物和方法
KR20160021823A (ko) 렉틴-유사 산화된 ldl 수용체1 항체 및 사용 방법
AU2014201433B2 (en) Compositions and methods for antibodies targeting complement protein C5
HK1202269B (en) Compositions and methods for antibodies targeting complement protein c5
HK1156226B (en) Compositions and methods for antibodies against complement protein c5
HK1157663B (en) Compositions and methods for antibodies targeting complement protein c5

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130501

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150310